The European Medicines Agency (EMA) is conducting a review of GLP-1 receptor agonists, including Ozempic, Saxenda, and Wegovy, used to treat type 2 diabetes and weight management, after reports of suicidal ideation and self-harm. The review was prompted by the Icelandic Medicines Agency following reports of these issues in people using liraglutide and semaglutide. The EMA has asked licence holders for evidence into associations with suicidal ideation and self-harm, and has analysed about 150 reports of possible cases. The review is ongoing and aims to assess the potential risks associated with these drugs.
Source link
GLP-1 receptor agonists: European drug regulator asks makers for evidence of self-harm
